Skip to main content
SpringerLink
Log in

Patients’ and Clinicians’ Experiences with In-person, Video, and Phone Modalities for Opioid Use Disorder Treatment: A Qualitative Study

  • Original Research: Qualitative Research
  • Published:
Journal of General Internal Medicine Aims and scope Submit manuscript

Abstract

Background

Opioid use disorder (OUD) is a chronic condition that requires regular visits and care continuity. Telehealth implementation has created multiple visit modalities for OUD care. There is limited knowledge of patients’ and clinicians’ perceptions and experiences related to multi-modality care and when different modalities might be best employed.

Objective

To identify patients’ and clinicians’ experiences with multiple visit modalities for OUD treatment in primary care.

Design

Comparative case study, using video- and telephone-based semi-structured interviews.

Participants

Patients being treated for OUD (n = 19) and clinicians who provided OUD care (n = 15) from two primary care clinics within the same healthcare system.

Approach

Using an inductive approach, interviews were analyzed to identify patients’ and clinicians’ experiences with receiving/delivering OUD care via different visit modalities. Clinicians’ and patients’ experiences were compared using a group analytical process.

Key Results

Patients and clinicians valued having multiple modalities available for care, with flexibility identified as a key benefit. Patients highlighted the decreased burden of travel and less social anxiety with telehealth visits. Similarly, clinicians reported that telehealth decreased medical intrusion into the lives of patients stable in recovery. Patients and clinicians saw the value of in-person visits when establishing care and for patients needing additional support. In-person visits allowed the ability to conduct urine drug testing, and to foster relationships and trust building, which were more difficult, but not impossible via a telehealth visit. Patients preferred telephone over video visits, as these were more private and more convenient. Clinicians identified benefits of video, including being able to both hear and see the patient, but often deferred to patient preference.

Conclusions

Considerations for utilization of visit modalities for OUD care were identified based on patients’ needs and preferences, which often changed over the course of treatment. Continued research is needed determine how visit modalities impact patient outcomes.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Oesterle TS, Kolla B, Risma CJ, et al. Substance Use Disorders and Telehealth in the COVID-19 Pandemic Era: A New Outlook. Mayo Clinic Proceedings. 2020;95(12):2709-2718. https://doi.org/10.1016/j.mayocp.2020.10.011

    Article  CAS  PubMed  Google Scholar 

  2. Uscher-Pines L, Riedel LE, Mehrotra A, Rose S, Busch AB, Huskamp HA. Many Clinicians Implement Digital Equity Strategies To Treat Opioid Use Disorder. Health Affairs. 2023;42(2):182-186. https://doi.org/10.1377/hlthaff.2022.00803

    Article  PubMed  Google Scholar 

  3. Bailey SR, Wyte-Lake T, Lucas JA, et al. Use of Telehealth for Opioid Use Disorder Treatment in Safety Net Primary Care Settings: A Mixed-Methods Study. Subst Use Misuse. 2023;58(9):1143-1151. https://doi.org/10.1080/10826084.2023.2212378

    Article  PubMed  Google Scholar 

  4. Textor L, Ventricelli D, Aronowitz SV. ‘Red Flags’ and ‘Red Tape’: Telehealth and pharmacy-level barriers to buprenorphine in the United States. Int J Drug Policy. 2022;105:103703. https://doi.org/10.1016/j.drugpo.2022.103703

    Article  PubMed  Google Scholar 

  5. Hughes PM, Verrastro G, Fusco CW, Wilson CG, Ostrach B. An examination of telehealth policy impacts on initial rural opioid use disorder treatment patterns during the COVID-19 pandemic. J Rural Health. 2021;37(3):467-472. https://doi.org/10.1111/jrh.12570

    Article  PubMed  PubMed Central  Google Scholar 

  6. Tilhou AS, Dague L, Saloner B, Beemon D, Burns M. Trends in Engagement With Opioid Use Disorder Treatment Among Medicaid Beneficiaries During the COVID-19 Pandemic. JAMA Health Forum. 2022;3(3):e220093-e220093. https://doi.org/10.1001/jamahealthforum.2022.0093

    Article  PubMed  PubMed Central  Google Scholar 

  7. Alexander K, Pogorzelska-Maziarz M, Gerolamo A, Hassen N, Kelly EL, Rising KL. The impact of COVID-19 on healthcare delivery for people who use opioids: a scoping review. Subst Abuse Treat Prev Policy. 2021;16(1):60. https://doi.org/10.1186/s13011-021-00395-6

    Article  PubMed  PubMed Central  Google Scholar 

  8. Cance JD, Doyle E. Changes in Outpatient Buprenorphine Dispensing During the COVID-19 Pandemic. JAMA. 2020;324(23):2442-2444. https://doi.org/10.1001/jama.2020.22154

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Thornton JD, Varisco TJ, Bapat SS, Downs CG, Shen C. Impact of COVID-19 Related Policy Changes on Buprenorphine Dispensing in Texas. J Addict Med. 2020;14(6):e372-e374. https://doi.org/10.1097/adm.0000000000000756

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Jones CM, Shoff C, Hodges K, et al. Receipt of Telehealth Services, Receipt and Retention of Medications for Opioid Use Disorder, and Medically Treated Overdose Among Medicare Beneficiaries Before and During the COVID-19 Pandemic. JAMA Psychiatry. 2022;https://doi.org/10.1001/jamapsychiatry.2022.2284

    Article  PubMed  PubMed Central  Google Scholar 

  11. Hailu R, Mehrotra A, Huskamp HA, Busch AB, Barnett ML. Telemedicine Use and Quality of Opioid Use Disorder Treatment in the US During the COVID-19 Pandemic. JAMA Network Open. 2023;6(1):e2252381-e2252381. https://doi.org/10.1001/jamanetworkopen.2022.52381

    Article  PubMed  PubMed Central  Google Scholar 

  12. Aronowitz SV, Engel-Rebitzer E, Dolan A, et al. Telehealth for opioid use disorder treatment in low-barrier clinic settings: an exploration of clinician and staff perspectives. Harm Reduction J. 2021;18(1):119. https://doi.org/10.1186/s12954-021-00572-7

    Article  Google Scholar 

  13. Cantone RE, Fleishman J, Garvey B, Gideonse N. Interdisciplinary Management of Opioid Use Disorder in Primary Care. Annals Family Med. 2018;16(1):83-83. https://doi.org/10.1370/afm.2184

    Article  Google Scholar 

  14. Mark TL, Treiman K, Padwa H, Henretty K, Tzeng J, Gilbert M. Addiction Treatment and Telehealth: Review of Efficacy and Provider Insights During the COVID-19 Pandemic. Psychiatr Serv. 2022;73(5):484-491. https://doi.org/10.1176/appi.ps.202100088

    Article  PubMed  Google Scholar 

  15. Sousa JL, Raja P, Huskamp HA, et al. Perspectives of Patients Receiving Telemedicine Services for Opioid Use Disorder Treatment: A Qualitative Analysis of User Experiences. J Addiction Med. 2022;16(6):702-708. https://doi.org/10.1097/adm.0000000000001006

    Article  Google Scholar 

  16. Uscher-Pines L, Sousa J, Raja P, Mehrotra A, Barnett M, Huskamp HA. Treatment of opioid use disorder during COVID-19: Experiences of clinicians transitioning to telemedicine. J Subst Abuse Treat. 2020;118:108124. https://doi.org/10.1016/j.jsat.2020.108124

    Article  PubMed  PubMed Central  Google Scholar 

  17. Lockard R, Priest KC, Gregg J, Buchheit BM. A qualitative study of patient experiences with telemedicine opioid use disorder treatment during COVID-19. Substance Abuse. 2022;43(1):1155-1162. https://doi.org/10.1080/08897077.2022.2060447

    Article  Google Scholar 

  18. Bailey SR, Wyte-Lake T, Lucas JA, et al. Use of Telehealth for Opioid Use Disorder Treatment in Safety Net Primary Care Settings: A Mixed-Methods Study. Substance Use Misuse. 2023:1-9. https://doi.org/10.1080/10826084.2023.2212378

  19. Lott AM, Danner AN, Malte CA, et al. Clinician Perspectives on Delivering Medication Treatment for Opioid Use Disorder during the COVID-19 Pandemic: A Qualitative Evaluation. J Addict Med. 2023;https://doi.org/10.1097/adm.0000000000001156

  20. Huskamp HA, Riedel L, Campa I, et al. Long-Term Prospects for Telemedicine in Opioid Use Disorder (OUD) Treatment: Results from a Longitudinal Survey of OUD Clinicians. J Gen Int Med. 2023:1-8.

  21. Al Hemyari B, Coffey N, Inman ZW, Singh A. Healthcare Providers’ Experience Using Telehealth During the Onset of the COVID-19 Pandemic in a Predominantly Rural Patient Base: An Online Survey. Cureus. 2023;15(3):e36260. https://doi.org/10.7759/cureus.36260

    Article  PubMed  PubMed Central  Google Scholar 

  22. Duff N, Freiling E, Burstin H, Clark K, Salman A. NAM Action Collaborative on Countering the U.S. Opioid Epidemic Telehealth and Virtual Care Meeting Series: Introduction to Improving Telehealth and Virtual Care for Pain Management and Opioid/Substance Use Disorder. 2022

  23. Frost MC, Zhang L, Kim HM, Lin L. Use of and Retention on Video, Telephone, and In-Person Buprenorphine Treatment for Opioid Use Disorder During the COVID-19 Pandemic. JAMA Network Open. 2022;5(10):e2236298-e2236298. https://doi.org/10.1001/jamanetworkopen.2022.36298

    Article  PubMed  PubMed Central  Google Scholar 

  24. Patel SY, Ortiz EG, Barsky BA, Huskamp HA, Busch AB, Mehrotra A. Patient and Clinician Characteristics Associated with Use of Telemedicine for Buprenorphine Induction Among Medicare Beneficiaries. J Gen Intern Med. 2022:1-4. https://doi.org/10.1007/s11606-022-07633-y

  25. Barsky BA, Busch AB, Patel SY, Mehrotra A, Huskamp HA. Use of Telemedicine for Buprenorphine Inductions in Patients With Commercial Insurance or Medicare Advantage. JAMA Network Open. 2022;5(1):e2142531-e2142531. https://doi.org/10.1001/jamanetworkopen.2021.42531

    Article  PubMed  PubMed Central  Google Scholar 

  26. Klee D, Pyne D, Kroll J, James W, Hirko KA. Rural patient and provider perceptions of telehealth implemented during the COVID-19 pandemic. BMC Health Serv Res.  2023;23(1):981. https://doi.org/10.1186/s12913-023-09994-4

    Article  PubMed  PubMed Central  Google Scholar 

  27. Angier H, Fleishman J, Gordon L, Cohen DJ, Cantone RE, Bailey SR. Tier-based treatment for opioid use disorder in the primary care setting. Fam Syst Health. 39(2):345-350. https://doi.org/10.1037/fsh0000619

    Article  PubMed  Google Scholar 

  28. Thomas DR. A general inductive approach for analyzing qualitative evaluation data. Ame J Eval. 2006;27(2):237-246.

    Article  Google Scholar 

  29. Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups. Int J Quality Health Care. 2007;19(6):349-357. https://doi.org/10.1093/intqhc/mzm042

    Article  Google Scholar 

  30. Guillen AG, Reddy M, Saadat S, Chakravarthy B. Utilization of Telehealth Solutions for Patients with Opioid Use Disorder Using Buprenorphine: A Scoping Review. Telemed J E Health. 2022;28(6):761-767. https://doi.org/10.1089/tmj.2021.0308

    Article  PubMed  Google Scholar 

  31. Uscher-Pines L, McCullough CM, Sousa JL, et al. Changes in In-Person, Audio-Only, and Video Visits in California’s Federally Qualified Health Centers, 2019-2022. JAMA. 2023;329(14):1219-1221. https://doi.org/10.1001/jama.2023.1307

    Article  PubMed  PubMed Central  Google Scholar 

  32. Lin LA, Zhang L, Kim HM, Frost MC. Impact of COVID-19 Telehealth Policy Changes on Buprenorphine Treatment for Opioid Use Disorder. Am J Psychiatry. 2022:appiajp21111141. https://doi.org/10.1176/appi.ajp.21111141

  33. Frost MC, Zhang L, Kim HM, Lin LA. Use of and retention on video, telephone, and in-person buprenorphine treatment for opioid use disorder during the COVID-19 pandemic. JAMA Network Open. 2022;5(10):e2236298-e2236298.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Sachs JW, Graven P, Gold JA, Kassakian SZ. Disparities in telephone and video telehealth engagement during the COVID-19 pandemic. JAMIA Open. 2021;4(3):ooab056. https://doi.org/10.1093/jamiaopen/ooab056

    Article  PubMed  PubMed Central  Google Scholar 

  35. National Trends in Telehealth Use in 2021:Disparities in Utilization and Audio vs. Video Services.(Research Report No.HP-2022-04) (Office of the Assistant Secretary for Planning and Evaluation, U. S. Department of Health and Human Services) (February 2022).

  36. Chen J, Li KY, Andino J, et al. Predictors of Audio-Only Versus Video Telehealth Visits During the COVID-19 Pandemic. J Gen Int Med. 2022;37(5):1138-1144. https://doi.org/10.1007/s11606-021-07172-y

    Article  Google Scholar 

  37. National Institute on Drug Abuse. Harm Reduction. Accessed December 4, 2023, https://nida.nih.gov/research-topics/harm-reduction

  38. Joseph G, Torres-Lockhart K, Stein MR, Mund PA, Nahvi S. Reimagining patient-centered care in opioid treatment programs: Lessons from the Bronx during COVID-19. Journal of substance abuse treatment. 2021;122:108219.

    Article  CAS  Google Scholar 

  39. Pytell JD, Rastegar DA. Down the drain: Reconsidering routine urine drug testing during the COVID-19 pandemic. J Substance Abuse Treat. 2021;120:108155. https://doi.org/10.1016/j.jsat.2020.108155

    Article  CAS  PubMed  Google Scholar 

  40. Knopf A. DEA proposes limits on telehealth for buprenorphine. Alcohol Drug Abuse Weekly. 2023;35(11):1-3. https://doi.org/10.1002/adaw.33712

    Article  Google Scholar 

  41. Temporary Extension of COVID-19 Telemedicine Flexibilities for Prescription of Controlled Medications. In: Drug Enforcement Administration, editor. 88 FR 300372023. 30037-30043.

  42. Hammerslag LR, Mack A, Chandler RK, et al. Telemedicine Buprenorphine Initiation and Retention in Opioid Use Disorder Treatment for Medicaid Enrollees. JAMA network open. 2023;6(10):e2336914-e2336914.

    Article  PubMed  PubMed Central  Google Scholar 

  43. Pham H, Lin C, Zhu Y, et al. Telemedicine-delivered treatment for substance use disorder: A scoping review. J Telemed Telecare. 2023:1357633X231190945.

Download references

Funding

Research reported in this publication was supported by the National Institute on Drug Abuse of the National Institutes of Health (#1R21DA054261-01) and the Agency for Healthcare Research and Quality (K12 HS026370). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or the Agency for Healthcare Research and Quality.

Author information

Authors and Affiliations

  1. Department of Family Medicine, Oregon Health & Science University, Portland, OR, USA

    Tamar Wyte-Lake DPT, MPH, Deborah J. Cohen PhD, Shannon Williams MSc, David Casey MSW, LCSW, CADC II, Matt Chan MD, Brian Frank MD, Ximena A. Levander MD, Dan Stein PA-C, Katie Kirkman White MSW, LCSW, MAC & Steffani R. Bailey PhD

Authors
  1. Tamar Wyte-Lake DPT, MPH
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Deborah J. Cohen PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Shannon Williams MSc
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. David Casey MSW, LCSW, CADC II
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Matt Chan MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Brian Frank MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Ximena A. Levander MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Dan Stein PA-C
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Katie Kirkman White MSW, LCSW, MAC
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Steffani R. Bailey PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tamar Wyte-Lake DPT, MPH.

Ethics declarations

Conflict of Interest:

The authors declare that they do not have a conflict of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Prior Presentations

A high-level summary of this paper was presented as a poster at the 2023 Academy Health Annual Research Meeting.

https://academyhealth.confex.com/academyhealth/2023arm/meetingapp.cgi/Paper/59702.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (DOCX 54.5 KB)

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wyte-Lake, T., Cohen, D.J., Williams, S. et al. Patients’ and Clinicians’ Experiences with In-person, Video, and Phone Modalities for Opioid Use Disorder Treatment: A Qualitative Study. J GEN INTERN MED (2024). https://doi.org/10.1007/s11606-023-08586-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s11606-023-08586-6

KEY WORDS

Search

Navigation